Abiopharma

New Form 3 - Cyclacel Pharmaceuticals, Inc. Filed: 2025-09-02 AccNo: 0001641172-25-026116 Size: 7 KB

New Form 6-K - Pharming Group N.V. Filed: 2025-09-02 AccNo: 0001828316-25-000039 Size: 201 KB

New Form 8-K - Rezolute, Inc. Filed: 2025-09-02 AccNo: 0001104659-25-085892 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - DuPont de Nemours, Inc. Filed: 2025-09-02 AccNo: 0001193125-25-193274 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form 8-K - IDEAYA Biosciences, Inc. Filed: 2025-09-02 AccNo: 0001193125-25-193238 Size: 141 KB Item 1.01: Entry into a Material Definitive Agreement

New Form 8-K - Cyclacel Pharmaceuticals, Inc. Filed: 2025-09-02 AccNo: 0001641172-25-026110 Size: 655 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form EFFECT - ONCOLYTICS BIOTECH INC Filed: 2025-08-29 AccNo: 9999999995-25-002795 Size: 1 KB

New Form EFFECT - ENZO BIOCHEM INC Filed: 2025-08-29 AccNo: 9999999995-25-002782 Size: 1 KB

New Form EFFECT - ENZO BIOCHEM INC Filed: 2025-08-29 AccNo: 9999999995-25-002783 Size: 1 KB

New Form S-8 - Fortrea Holdings Inc. Filed: 2025-08-29 AccNo: 0001965040-25-000095 Size: 229 KB

New Form S-8 - Fortrea Holdings Inc. Filed: 2025-08-29 AccNo: 0001965040-25-000094 Size: 600 KB

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

ICON plc to Participate at Upcoming Investor Conferences

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference